BioLife Solutions (NASDAQ:BLFS - Get Free Report) had its target price lifted by stock analysts at Northland Securities from $28.00 to $31.00 in a note issued to investors on Wednesday,Benzinga reports. The firm presently has an "outperform" rating on the medical equipment provider's stock. Northland Securities' target price suggests a potential upside of 11.95% from the stock's current price.
Several other research analysts have also recently issued reports on the company. TD Cowen upped their price objective on BioLife Solutions from $28.00 to $31.00 and gave the stock a "buy" rating in a research report on Wednesday, November 13th. HC Wainwright lowered their price target on BioLife Solutions from $29.00 to $27.00 and set a "buy" rating for the company in a report on Monday, November 18th. Craig Hallum raised their price objective on shares of BioLife Solutions from $30.00 to $32.00 and gave the stock a "buy" rating in a report on Wednesday, November 13th. Benchmark restated a "buy" rating and set a $30.00 price objective on shares of BioLife Solutions in a research report on Thursday, December 19th. Finally, KeyCorp increased their target price on shares of BioLife Solutions from $30.00 to $33.00 and gave the company an "overweight" rating in a research report on Friday, December 13th. One equities research analyst has rated the stock with a sell rating and seven have given a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $29.43.
Check Out Our Latest Stock Report on BLFS
BioLife Solutions Stock Up 2.1 %
Shares of BioLife Solutions stock traded up $0.58 on Wednesday, reaching $27.69. 270,111 shares of the company were exchanged, compared to its average volume of 217,162. The stock's 50 day moving average price is $25.91 and its 200-day moving average price is $24.27. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.78 and a quick ratio of 1.78. BioLife Solutions has a 1-year low of $14.50 and a 1-year high of $28.88. The company has a market cap of $1.28 billion, a P/E ratio of -26.12 and a beta of 1.92.
Insider Activity at BioLife Solutions
In related news, EVP Aby J. Mathew sold 17,604 shares of BioLife Solutions stock in a transaction on Monday, November 18th. The shares were sold at an average price of $20.05, for a total value of $352,960.20. Following the transaction, the executive vice president now directly owns 284,442 shares in the company, valued at $5,703,062.10. This trade represents a 5.83 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO Troy Wichterman sold 987 shares of the company's stock in a transaction on Monday, January 6th. The stock was sold at an average price of $27.02, for a total transaction of $26,668.74. Following the transaction, the chief financial officer now owns 121,779 shares of the company's stock, valued at approximately $3,290,468.58. The trade was a 0.80 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 113,129 shares of company stock worth $2,576,818 in the last 90 days. 2.20% of the stock is owned by insiders.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently made changes to their positions in the company. State Street Corp boosted its holdings in BioLife Solutions by 7.3% in the 3rd quarter. State Street Corp now owns 1,412,316 shares of the medical equipment provider's stock valued at $35,364,000 after purchasing an additional 95,788 shares in the last quarter. Geode Capital Management LLC lifted its holdings in shares of BioLife Solutions by 2.2% in the 3rd quarter. Geode Capital Management LLC now owns 842,771 shares of the medical equipment provider's stock valued at $21,107,000 after buying an additional 18,473 shares during the period. The Manufacturers Life Insurance Company boosted its stake in shares of BioLife Solutions by 40.8% in the third quarter. The Manufacturers Life Insurance Company now owns 19,463 shares of the medical equipment provider's stock valued at $487,000 after buying an additional 5,638 shares in the last quarter. Barclays PLC grew its holdings in BioLife Solutions by 20.1% during the third quarter. Barclays PLC now owns 64,423 shares of the medical equipment provider's stock worth $1,613,000 after acquiring an additional 10,803 shares during the period. Finally, Mutual of America Capital Management LLC purchased a new position in BioLife Solutions in the second quarter worth $8,592,000. 93.24% of the stock is currently owned by institutional investors and hedge funds.
About BioLife Solutions
(
Get Free Report)
BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.
See Also
Before you consider BioLife Solutions, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioLife Solutions wasn't on the list.
While BioLife Solutions currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
